MEDIORG
Medicamen Organics financials
- Market cap
- ₹36 Cr
- Sector
- Healthcare
- Calls analysed
- 1
MEDIORG Q4 FY25
What went well
- Revenue of INR38.18 crores, up 51% YoY in FY25, reflecting strong growth.
- PAT of INR4.04 crores, surged 54% YoY in FY25, indicating improved operational efficiency.
- Strategic entry into the Nepalese market by acquiring a 30% stake in Medi Hub Organic Limited.
What to watch
- High debtor days, particularly from government institutions and French West Africa, leading to a 6-month receivable cycle.
- Operating margins saw some decline, though specific figures for the decline were not provided, with an EBITDA margin target of ~24%.
What Medicamen Organics Ltd does
Medicamen Organics develops, manufactures and distributes generic pharmaceutical dosage forms - tablets, capsules, oral liquids, ointments/gels, syrups, suspensions and dry powders - largely as a contract/third-party manufacturer for government and private institutions. It sells to private pharma companies in India and international markets (Africa, CIS, South-East Asia) through third-party distributors or on loan-license basis. Manufacturing is carried out at two WHO-GMP certified facilities in Haridwar, Uttarakhand. The company is expanding via subsidiaries into direct international distribution (Rwanda, Nepal) and has entered cosmetics/personal care under its own LOIRE brand.
Segments
- Pharmaceutical formulations
- Cosmetics & personal care
- International distribution subsidiaries
- Manufacturing facilities
- 2 WHO-GMP approved units, SIDCUL, Haridwar, Uttarakhand
- Installed tablet capacity
- 21,600 lakh tablets/yr (Unit I 10,800 + Unit II 10,800 lakh tablets)
- Installed capsule capacity
- 780 lakh capsules/yr (Unit II)
- Installed suspension capacity
- 936,000 litres/yr (Unit II)
- Installed ointment capacity
- 93,600 kg/yr (Unit II)
- Installed dry-powder sachet capacity
- 3,744,000 sachets/yr (Unit II)
Guidance record · Q4 FY25
what the last two calls moved 9 tracked 0 delivered 0 missed 9 open- Revenue open said Q4 FY25 Promised: INR60 crores to INR65 crores for FY '26 Q4 FY25: Target set for FY26
All 9 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q4 FY26: revenue down 65.7%, net profit down 581.0% against the same quarter last year.
| Line item | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|
| Revenue | 14 | 17 | 22 | 18 | 5 −66% |
| EBITDA | 2 | 3 | 4 | 3 | -7 −408% |
| Net profit | 1 | 2 | 3 | 2 | -6 −581% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −29.6% 1Y
1Y: ₹34 on 10 Sept 2025 → ₹23.95. High ₹37.9 (28 Oct 2025), low ₹19.4 (12 Jun 2026).
Balance sheet
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Equity capital | ₹9 Cr | ₹12 Cr | ₹12 Cr |
| Reserves | ₹7 Cr | ₹21 Cr | ₹17 Cr |
| Borrowings | ₹13 Cr | ₹16 Cr | ₹14 Cr |
| Other liabilities | ₹11 Cr | ₹13 Cr | ₹9 Cr |
| Total liabilities | ₹38 Cr | ₹61 Cr | ₹52 Cr |
| Fixed assets | ₹10 Cr | ₹13 Cr | ₹13 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹28 Cr | ₹48 Cr | ₹38 Cr |
| Total assets | ₹38 Cr | ₹61 Cr | ₹52 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Mar 2025, the public added +8.64 pp while promoters trimmed −4.84 pp. The shareholder count grew 10% to 508.
- Promoters
- 54.9%
- FIIs
- 0.1%
- Public
- 45.0%
Since Mar 2025
- Public +8.64 pp
- Promoters −4.84 pp
- DIIs −3.79 pp
How it drifted, 5 quarters
Over this window the public went from 36.4% to 45.0% — +8.6 pp.
Ownership split by quarter, oldest first. Sep '24: Promoters 59.7%, FIIs 0.1%, DIIs 3.8%, Public 36.4%.Mar '25: Promoters 59.7%, FIIs 0.1%, DIIs 3.8%, Public 36.4%.Sep '25: Promoters 59.7%, FIIs 0.1%, DIIs 3.7%, Public 36.5%.Mar '26: Promoters 59.7%, FIIs 0.1%, DIIs 1.6%, Public 38.6%.Jun '26: Promoters 54.9%, FIIs 0.1%, Public 45.0%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Pradeep Kumar Jain newly disclosed 13.92% held
- Shivani Chopra newly disclosed 4.03% held
- Pawan Kumar Gupta newly disclosed 1.02% held
- Abhishek Kaushik +0.91 pp 2.12% held
The same filing shows 3 holders trimming and 2 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Medicamen Organics Ltd above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Balkishan Gupta | 48.94% | −3.22 pp |
| Pradeep Kumar Jain | 13.92% | newly disclosed |
| Shivani Chopra | 4.03% | newly disclosed |
| Ashutosh Gupta | 3.97% | −1.08 pp |
| Abhishek Kaushik | 2.12% | +0.91 pp |
| Ritu Gupta | 1.93% | −0.52 pp |
| Pawan Kumar Gupta | 1.02% | newly disclosed |
| Ishaan Gupta | 0.05% | unchanged |
| Bkgupta & Sons . | 0.00% | unchanged |
| Sb Opportunities Fund I AIF | — | off the list |
| Akilandeswari Selvamurthy | — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Medicamen Organics Ltd
Guides on how to read this kind of business and the numbers that matter.